Real-world study of a treatment for moderate to severe inflammatory bowel disease

This is a real-world observational study of upadacitinib, a medication already approved to treat moderate to severe Crohn's disease. Researchers want to understand how well the medication works and what side effects patients experience when using it in regular clinical practice in Japan. Your doctors will prescribe and manage the medication as they normally would—the study simply tracks your progress over time.

Crohn's disease is a chronic inflammatory condition of the digestive tract that can significantly impact quality of life. While this medication has been approved for treatment, researchers want to learn more about how it performs in real-world settings outside of controlled clinical trials, so they can better understand its safety and effectiveness for Japanese patients.